The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Insights into the Phase II TIDAL study
Tycel Phillips, MD, City of Hope, Duarte, CA, shares some insights into the Phase II TIDAL study (NCT03768505), which is evaluating the safety and efficacy of zandelisib in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL) who have failed at least two prior lines of therapy. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
